Europe Prescription Drugs Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Branded and Generics), Drug Type (Small Molecule and Biologics and Biosimilar), Therapeutic Area (Oncology, Cardiovascular Diseases, Neurological Diseases, Metabolic Diseases, Respiratory Diseases, Immunology, and Others), Route Of Administration (Oral, Injectable, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
The Europe Prescription Drugs Market is projected to grow significantly, reaching an estimated US$ 537.6 billion by 2031, up from US$ 335.0 billion in 2024, reflecting a compound annual growth rate (CAGR) of 7.0% from 2025 to 2031. This growth is primarily driven by several key factors, including the rising prevalence of chronic diseases, an aging population, advancements in medical research, and improvements in healthcare infrastructure.
The increasing incidence of chronic diseases such as diabetes, cardiovascular conditions, and cancer is a major contributor to the demand for prescription medications. As the population ages, older adults often require more pharmaceutical interventions to manage multiple health issues, leading to higher consumption of prescription drugs. Furthermore, innovations in medical research and biotechnology have resulted in the development of new therapies, including biologics and personalized medicine, which are increasingly being prescribed and tend to have a higher market value.
Improvements in healthcare infrastructure across Europe have also facilitated earlier diagnosis and treatment, which in turn has led to increased prescription rates. Government initiatives aimed at promoting preventive healthcare and raising public awareness about disease management encourage patients to seek medical advice and adhere to prescribed treatments. This trend is further supported by rising healthcare expenditures from both public and private sectors, which enhance reimbursement policies and improve drug availability.
The pharmaceutical research and development (R&D) landscape in Europe is robust, with significant investments leading to a strong pipeline of new drugs, particularly in areas with unmet medical needs. Although regulatory frameworks in Europe are stringent, they provide a clear pathway for drug approval, which encourages innovation and market entry for pharmaceutical companies. Additionally, the rise of digital health technologies, such as telemedicine and electronic prescriptions, has improved patient access to healthcare providers and medications, further driving market growth.
The Europe Prescription Drugs Market can be segmented by product type into branded and generics, with branded drugs holding the largest market share in 2024. By drug type, the market is divided into small molecules and biologics/biosimilars, where small molecules dominate. Therapeutically, oncology is the leading area, followed by cardiovascular and neurological diseases. In terms of administration routes, oral medications are the most common, while hospital pharmacies are the primary distribution channel.
Innovative drugs, particularly specialty medications for complex and chronic conditions, are reshaping the pharmaceutical landscape. These drugs, which include treatments for diseases like multiple sclerosis and cancer, often come with high costs and specific handling requirements. The growing prevalence of such specialty drugs is driven by technological advancements, increasing unmet medical needs, and favorable regulatory environments. For instance, gene therapies like Luxturna, which target previously untreatable conditions, exemplify the breakthroughs in treatment options available today. Companies are also focusing on personalized medicine, tailoring treatments based on genetic profiles to enhance efficacy and minimize side effects.
In terms of geographical insights, the market is segmented into key countries including Germany, the United Kingdom, France, Italy, and Spain, with Germany holding the largest market share in 2024. The high incidence of chronic diseases in Germany, such as cardiovascular diseases and cancer, necessitates a greater demand for prescription drugs. For example, approximately 0.60 million new cancer cases were reported in Germany in 2022, highlighting the urgent need for effective pharmaceutical interventions.
Corporate developments within the pharmaceutical sector are noteworthy. For instance, Boehringer Ingelheim has recently surpassed Bayer to become Germany's largest drugmaker, driven by a 10.3% increase in pharmaceutical sales, largely attributed to its diabetes medication, Jardiance. Similarly, Gerresheimer anticipates steady revenue growth from supplying packaging solutions for weight loss and diabetes drugs, particularly GLP-1 medications.
Key players in the Prescription Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi SA, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, and Eli Lilly and Co. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.
In summary, the Europe Prescription Drugs Market is poised for substantial growth driven by chronic disease prevalence, an aging population, advancements in drug development, and improved healthcare access. The market dynamics are further influenced by strategic corporate actions and the ongoing evolution of healthcare technologies.
The increasing incidence of chronic diseases such as diabetes, cardiovascular conditions, and cancer is a major contributor to the demand for prescription medications. As the population ages, older adults often require more pharmaceutical interventions to manage multiple health issues, leading to higher consumption of prescription drugs. Furthermore, innovations in medical research and biotechnology have resulted in the development of new therapies, including biologics and personalized medicine, which are increasingly being prescribed and tend to have a higher market value.
Improvements in healthcare infrastructure across Europe have also facilitated earlier diagnosis and treatment, which in turn has led to increased prescription rates. Government initiatives aimed at promoting preventive healthcare and raising public awareness about disease management encourage patients to seek medical advice and adhere to prescribed treatments. This trend is further supported by rising healthcare expenditures from both public and private sectors, which enhance reimbursement policies and improve drug availability.
The pharmaceutical research and development (R&D) landscape in Europe is robust, with significant investments leading to a strong pipeline of new drugs, particularly in areas with unmet medical needs. Although regulatory frameworks in Europe are stringent, they provide a clear pathway for drug approval, which encourages innovation and market entry for pharmaceutical companies. Additionally, the rise of digital health technologies, such as telemedicine and electronic prescriptions, has improved patient access to healthcare providers and medications, further driving market growth.
The Europe Prescription Drugs Market can be segmented by product type into branded and generics, with branded drugs holding the largest market share in 2024. By drug type, the market is divided into small molecules and biologics/biosimilars, where small molecules dominate. Therapeutically, oncology is the leading area, followed by cardiovascular and neurological diseases. In terms of administration routes, oral medications are the most common, while hospital pharmacies are the primary distribution channel.
Innovative drugs, particularly specialty medications for complex and chronic conditions, are reshaping the pharmaceutical landscape. These drugs, which include treatments for diseases like multiple sclerosis and cancer, often come with high costs and specific handling requirements. The growing prevalence of such specialty drugs is driven by technological advancements, increasing unmet medical needs, and favorable regulatory environments. For instance, gene therapies like Luxturna, which target previously untreatable conditions, exemplify the breakthroughs in treatment options available today. Companies are also focusing on personalized medicine, tailoring treatments based on genetic profiles to enhance efficacy and minimize side effects.
In terms of geographical insights, the market is segmented into key countries including Germany, the United Kingdom, France, Italy, and Spain, with Germany holding the largest market share in 2024. The high incidence of chronic diseases in Germany, such as cardiovascular diseases and cancer, necessitates a greater demand for prescription drugs. For example, approximately 0.60 million new cancer cases were reported in Germany in 2022, highlighting the urgent need for effective pharmaceutical interventions.
Corporate developments within the pharmaceutical sector are noteworthy. For instance, Boehringer Ingelheim has recently surpassed Bayer to become Germany's largest drugmaker, driven by a 10.3% increase in pharmaceutical sales, largely attributed to its diabetes medication, Jardiance. Similarly, Gerresheimer anticipates steady revenue growth from supplying packaging solutions for weight loss and diabetes drugs, particularly GLP-1 medications.
Key players in the Prescription Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi SA, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, and Eli Lilly and Co. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.
In summary, the Europe Prescription Drugs Market is poised for substantial growth driven by chronic disease prevalence, an aging population, advancements in drug development, and improved healthcare access. The market dynamics are further influenced by strategic corporate actions and the ongoing evolution of healthcare technologies.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. PRESCRIPTION DRUGS MARKET LANDSCAPE
4.1 PEST Analysis
5. EUROPE PRESCRIPTION DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. PRESCRIPTION DRUGS MARKET - EUROPE MARKET ANALYSIS
6.1 Europe Prescription Drugs Market Revenue (US$ Billion), 2024 - 2031
6.2 Europe Prescription Drugs Market Forecast and Analysis
7. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Branded
7.1.1 Overview
7.1.2 Branded: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
7.2 Generics
7.2.1 Overview
7.2.2 Generics: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
8. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY DRUG TYPE
8.1 Small Molecule
8.1.1 Overview
8.1.2 Small Molecule: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
8.2 Biologics and Biosimilars
8.2.1 Overview
8.2.2 Biologics and Biosimilars: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.2 Cardiovascular Diseases
9.2.1 Overview
9.2.2 Cardiovascular Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.3 Neurological Diseases
9.3.1 Overview
9.3.2 Neurological Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.4 Metabolic Diseases
9.4.1 Overview
9.4.2 Metabolic Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.5 Respiratory Diseases
9.5.1 Overview
9.5.2 Respiratory Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.6 Immunology
9.6.1 Overview
9.6.2 Immunology: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.7 Others
9.7.1 Overview
9.7.2 Others: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
10.1 Oral
10.1.1 Overview
10.1.2 Oral: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.2 Injectable
10.2.1 Overview
10.2.2 Injectable: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.3 Topical
10.3.1 Overview
10.3.2 Topical: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.4 Others
10.4.1 Overview
10.4.2 Others: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12. EUROPE PRESCRIPTION DRUGS MARKET - COUNTRY ANALYSIS
12.1 Europe
12.1.1 Europe Prescription Drugs Market Revenue and Forecast and Analysis - by Country
12.1.1.1 Europe Prescription Drugs Market Revenue and Forecast and Analysis - by Country
12.1.2.2 Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.1.2.2.1 Germany: Europe Prescription Drugs Market Share - by Product Type
12.1.2.2.2 Germany: Europe Prescription Drugs Market Share - by Drug Type
12.1.2.2.3 Germany: Europe Prescription Drugs Market Share - by Therapeutic Area
12.1.2.2.4 Germany: Europe Prescription Drugs Market Share - by Route Of Administration
12.1.2.2.5 Germany: Europe Prescription Drugs Market Share - by Distribution Channel
12.2.3.3 United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.2.3.3.1 United Kingdom: Europe Prescription Drugs Market Share - by Product Type
12.2.3.3.2 United Kingdom: Europe Prescription Drugs Market Share - by Drug Type
12.2.3.3.3 United Kingdom: Europe Prescription Drugs Market Share - by Therapeutic Area
12.2.3.3.4 United Kingdom: Europe Prescription Drugs Market Share - by Route Of Administration
12.2.3.3.5 United Kingdom: Europe Prescription Drugs Market Share - by Distribution Channel
12.3.4.4 France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.3.4.4.1 France: Europe Prescription Drugs Market Share - by Product Type
12.3.4.4.2 France: Europe Prescription Drugs Market Share - by Drug Type
12.3.4.4.3 France: Europe Prescription Drugs Market Share - by Therapeutic Area
12.3.4.4.4 France: Europe Prescription Drugs Market Share - by Route Of Administration
12.3.4.4.5 France: Europe Prescription Drugs Market Share - by Distribution Channel
12.4.5.5 Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.4.5.5.1 Italy: Europe Prescription Drugs Market Share - by Product Type
12.4.5.5.2 Italy: Europe Prescription Drugs Market Share - by Drug Type
12.4.5.5.3 Italy: Europe Prescription Drugs Market Share - by Therapeutic Area
12.4.5.5.4 Italy: Europe Prescription Drugs Market Share - by Route Of Administration
12.4.5.5.5 Italy: Europe Prescription Drugs Market Share - by Distribution Channel
12.5.6.6 Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.5.6.6.1 Spain: Europe Prescription Drugs Market Share - by Product Type
12.5.6.6.2 Spain: Europe Prescription Drugs Market Share - by Drug Type
12.5.6.6.3 Spain: Europe Prescription Drugs Market Share - by Therapeutic Area
12.5.6.6.4 Spain: Europe Prescription Drugs Market Share - by Route Of Administration
12.5.6.6.5 Spain: Europe Prescription Drugs Market Share - by Distribution Channel
12.6.7.7 Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.6.7.7.1 Rest of Europe: Europe Prescription Drugs Market Share - by Product Type
12.6.7.7.2 Rest of Europe: Europe Prescription Drugs Market Share - by Drug Type
12.6.7.7.3 Rest of Europe: Europe Prescription Drugs Market Share - by Therapeutic Area
12.6.7.7.4 Rest of Europe: Europe Prescription Drugs Market Share - by Route Of Administration
12.6.7.7.5 Rest of Europe: Europe Prescription Drugs Market Share - by Distribution Channel
13 COMPETITIVE LANDSCAPE
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning & Concentration
14 INDUSTRY LANDSCAPE
14.1 Overview
14.2 New Product Development
14.3 Merger and Acquisition
14.4 Other Strategic Developments
15 COMPANY PROFILES
15.1 GSK Plc
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 F. Hoffmann-La Roche Ltd
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Pfizer Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Merck & Co Inc
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Teva Pharmaceutical Industries Ltd
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Novartis AG
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Sanofi SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Johnson & Johnson
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 AstraZeneca Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 AbbVie Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 Eli Lilly and Co
15.11.1 Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 ESTEVE
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
16. APPENDIX
16.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. PRESCRIPTION DRUGS MARKET LANDSCAPE
4.1 PEST Analysis
5. EUROPE PRESCRIPTION DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. PRESCRIPTION DRUGS MARKET - EUROPE MARKET ANALYSIS
6.1 Europe Prescription Drugs Market Revenue (US$ Billion), 2024 - 2031
6.2 Europe Prescription Drugs Market Forecast and Analysis
7. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Branded
7.1.1 Overview
7.1.2 Branded: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
7.2 Generics
7.2.1 Overview
7.2.2 Generics: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
8. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY DRUG TYPE
8.1 Small Molecule
8.1.1 Overview
8.1.2 Small Molecule: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
8.2 Biologics and Biosimilars
8.2.1 Overview
8.2.2 Biologics and Biosimilars: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.2 Cardiovascular Diseases
9.2.1 Overview
9.2.2 Cardiovascular Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.3 Neurological Diseases
9.3.1 Overview
9.3.2 Neurological Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.4 Metabolic Diseases
9.4.1 Overview
9.4.2 Metabolic Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.5 Respiratory Diseases
9.5.1 Overview
9.5.2 Respiratory Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.6 Immunology
9.6.1 Overview
9.6.2 Immunology: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.7 Others
9.7.1 Overview
9.7.2 Others: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
10.1 Oral
10.1.1 Overview
10.1.2 Oral: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.2 Injectable
10.2.1 Overview
10.2.2 Injectable: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.3 Topical
10.3.1 Overview
10.3.2 Topical: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.4 Others
10.4.1 Overview
10.4.2 Others: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11. EUROPE PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12. EUROPE PRESCRIPTION DRUGS MARKET - COUNTRY ANALYSIS
12.1 Europe
12.1.1 Europe Prescription Drugs Market Revenue and Forecast and Analysis - by Country
12.1.1.1 Europe Prescription Drugs Market Revenue and Forecast and Analysis - by Country
12.1.2.2 Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.1.2.2.1 Germany: Europe Prescription Drugs Market Share - by Product Type
12.1.2.2.2 Germany: Europe Prescription Drugs Market Share - by Drug Type
12.1.2.2.3 Germany: Europe Prescription Drugs Market Share - by Therapeutic Area
12.1.2.2.4 Germany: Europe Prescription Drugs Market Share - by Route Of Administration
12.1.2.2.5 Germany: Europe Prescription Drugs Market Share - by Distribution Channel
12.2.3.3 United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.2.3.3.1 United Kingdom: Europe Prescription Drugs Market Share - by Product Type
12.2.3.3.2 United Kingdom: Europe Prescription Drugs Market Share - by Drug Type
12.2.3.3.3 United Kingdom: Europe Prescription Drugs Market Share - by Therapeutic Area
12.2.3.3.4 United Kingdom: Europe Prescription Drugs Market Share - by Route Of Administration
12.2.3.3.5 United Kingdom: Europe Prescription Drugs Market Share - by Distribution Channel
12.3.4.4 France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.3.4.4.1 France: Europe Prescription Drugs Market Share - by Product Type
12.3.4.4.2 France: Europe Prescription Drugs Market Share - by Drug Type
12.3.4.4.3 France: Europe Prescription Drugs Market Share - by Therapeutic Area
12.3.4.4.4 France: Europe Prescription Drugs Market Share - by Route Of Administration
12.3.4.4.5 France: Europe Prescription Drugs Market Share - by Distribution Channel
12.4.5.5 Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.4.5.5.1 Italy: Europe Prescription Drugs Market Share - by Product Type
12.4.5.5.2 Italy: Europe Prescription Drugs Market Share - by Drug Type
12.4.5.5.3 Italy: Europe Prescription Drugs Market Share - by Therapeutic Area
12.4.5.5.4 Italy: Europe Prescription Drugs Market Share - by Route Of Administration
12.4.5.5.5 Italy: Europe Prescription Drugs Market Share - by Distribution Channel
12.5.6.6 Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.5.6.6.1 Spain: Europe Prescription Drugs Market Share - by Product Type
12.5.6.6.2 Spain: Europe Prescription Drugs Market Share - by Drug Type
12.5.6.6.3 Spain: Europe Prescription Drugs Market Share - by Therapeutic Area
12.5.6.6.4 Spain: Europe Prescription Drugs Market Share - by Route Of Administration
12.5.6.6.5 Spain: Europe Prescription Drugs Market Share - by Distribution Channel
12.6.7.7 Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.6.7.7.1 Rest of Europe: Europe Prescription Drugs Market Share - by Product Type
12.6.7.7.2 Rest of Europe: Europe Prescription Drugs Market Share - by Drug Type
12.6.7.7.3 Rest of Europe: Europe Prescription Drugs Market Share - by Therapeutic Area
12.6.7.7.4 Rest of Europe: Europe Prescription Drugs Market Share - by Route Of Administration
12.6.7.7.5 Rest of Europe: Europe Prescription Drugs Market Share - by Distribution Channel
13 COMPETITIVE LANDSCAPE
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning & Concentration
14 INDUSTRY LANDSCAPE
14.1 Overview
14.2 New Product Development
14.3 Merger and Acquisition
14.4 Other Strategic Developments
15 COMPANY PROFILES
15.1 GSK Plc
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 F. Hoffmann-La Roche Ltd
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Pfizer Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Merck & Co Inc
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Teva Pharmaceutical Industries Ltd
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Novartis AG
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Sanofi SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Johnson & Johnson
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 AstraZeneca Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 AbbVie Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 Eli Lilly and Co
15.11.1 Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 ESTEVE
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
16. APPENDIX
16.1 About The Insight Partners
LIST OF TABLES
Table 1. Europe Prescription Drugs Market Segmentation
Table 3. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Table 4. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 5. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 6. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 7. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 8. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 9. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Country
Table 10. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 11. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 12. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 13. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 14. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 15. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 16. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 17. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 18. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 19. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 20. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 21. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 22. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 23. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 24. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 25. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 26. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 27. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 28. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 29. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 30. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 31. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 32. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 33. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 34. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 35. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 36. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 37. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 38. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 39. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 40. Heat Map Analysis by Key Players
Table 1. Europe Prescription Drugs Market Segmentation
Table 3. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Table 4. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 5. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 6. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 7. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 8. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 9. Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Country
Table 10. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 11. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 12. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 13. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 14. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 15. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 16. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 17. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 18. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 19. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 20. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 21. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 22. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 23. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 24. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 25. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 26. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 27. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 28. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 29. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 30. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 31. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 32. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 33. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 34. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 35. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 36. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 37. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 38. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 39. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 40. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Europe Prescription Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Europe Prescription Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Europe Prescription Drugs Market Revenue (US$ Billion), 2024 - 2031
Figure 7. Europe Prescription Drugs Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Branded: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 9. Generics: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 10. Europe Prescription Drugs Market Share (%) - by Drug Type, 2024 and 2031
Figure 11. Small Molecule: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 12. Biologics and Biosimilar: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 13. Europe Prescription Drugs Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 14. Oncology: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 15. Cardiovascular Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 16. Neurological Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 17. Metabolic Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 18. Respiratory Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 19. Immunology: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 20. Others: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 21. Europe Prescription Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 22. Oral: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 23. Injectable: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 24. Topical: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 25. Others: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 26. Europe Prescription Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 27. Hospital Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 28. Retail Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 29. Online Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 30. Europe Prescription Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 31. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 32. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 33. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 34. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 35. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 36. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 37. Company Positioning & Concentration
Figure 1. Europe Prescription Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Europe Prescription Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Europe Prescription Drugs Market Revenue (US$ Billion), 2024 - 2031
Figure 7. Europe Prescription Drugs Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Branded: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 9. Generics: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 10. Europe Prescription Drugs Market Share (%) - by Drug Type, 2024 and 2031
Figure 11. Small Molecule: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 12. Biologics and Biosimilar: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 13. Europe Prescription Drugs Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 14. Oncology: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 15. Cardiovascular Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 16. Neurological Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 17. Metabolic Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 18. Respiratory Diseases: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 19. Immunology: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 20. Others: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 21. Europe Prescription Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 22. Oral: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 23. Injectable: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 24. Topical: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 25. Others: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 26. Europe Prescription Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 27. Hospital Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 28. Retail Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 29. Online Pharmacies: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 30. Europe Prescription Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 31. Germany: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 32. United Kingdom: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 33. France: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 34. Italy: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 35. Spain: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 36. Rest of Europe: Europe Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 37. Company Positioning & Concentration
